<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59277">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02334306</url>
  </required_header>
  <id_info>
    <org_study_id>D5181C00001</org_study_id>
    <nct_id>NCT02334306</nct_id>
  </id_info>
  <brief_title>A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome</brief_title>
  <official_title>A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a study to evaluate the efficacy and safety of AMG 557/MEDI5872 in Primary
      Sjögren's Syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled,
      parallel-group study to evaluate the clinical and biologic efficacy, as well as the safety
      of SC doses of AMG 557/MEDI5872 in adult subjects with Primary Sjögren's Syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) score from Day 1 to Day 99</measure>
    <time_frame>Day 1 to Day 99</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcomes in peripheral blood - Change in plasma cell (PC) levels (including plasma blast [PB] levels) from baseline to Day 99</measure>
    <time_frame>Day 1 to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes in minor salivary gland tissue - Change in PC levels from baseline to Day 99</measure>
    <time_frame>Day 1 to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in focus score from Day 1 to Day 99</measure>
    <time_frame>Day 1 to Day 99</time_frame>
    <description>Focus score is an assessment of salivary gland inflammation that measures the number of lymphocytes in a 4 mm2 area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of multiple subcutaneous (SC) doses of AMG 557/MEDI5872 as measured by safety laboratory tests (hematology, chemistry and urinalysis)</measure>
    <time_frame>Day 1 to Day 281</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in European League Against Rheumatism Sjogren's Syndrome Patient Reported Index (ESSPRI) score from Day 1 to Day 99</measure>
    <time_frame>Day 1 to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes in peripheral blood - Change in follicular helper T cells (TFH) levels from Day 1 to Day 99</measure>
    <time_frame>Day 1 to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes in minor salivary gland tissue - Change in TFH levels from Day 1 to Day 99</measure>
    <time_frame>Day 1 to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of multiple subcutaneous (SC) doses of AMG 557/MEDI5872 as measured by the number of subjects with adverse events, including serious adverse events, treatment-related adverse events and adverse events of special interest</measure>
    <time_frame>Day 1 to Day 281</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Primary Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>AMG 557/MEDI5872</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed subcutaneous (SC) dose of AMG 557/MEDI5872 every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85). Beginning on Day 99, all subjects (n = 42) will receive a fixed SC dose of AMG 557/MEDI5872 every week (Days 99 to 113) and every 2 weeks (Days 127 to 183) for an additional 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fixed SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85). Beginning on Day 99, all subjects (n = 42) will receive a fixed SC dose of AMG 557/MEDI5872 every week (Days 99 to 113) and every 2 weeks (Days 127 to 183) for an additional 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 557/MEDI5872</intervention_name>
    <description>Fixed subcutaneous (SC) dose of AMG 557/MEDI5872 every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85). Beginning on Day 99, all subjects (n = 42) will receive a fixed SC dose of AMG 557/MEDI5872 every week (Days 99 to 113) and every 2 weeks (Days 127 to 183) for an additional 12 weeks.</description>
    <arm_group_label>AMG 557/MEDI5872</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Fixed SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85). Beginning on Day 99, all subjects (n = 42) will receive a fixed SC dose of AMG 557/MEDI5872 every week (Days 99 to 113) and every 2 weeks (Days 127 to 183) for an additional 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 through 75 years at the time of signing the ICF.

          -  Fulfill American-European Consensus Group (AECG) criteria for pSS

          -  ESSDAI score ≥ 6.

          -  Positive anti-SS-A and/or anti-SS-B autoantibodies and at least IgG &gt; 13 g/L or RF
             level &gt; upper limit of normal (ULN) or positive test for cryoglobulins

          -  Willingness to undergo protocol-required minor salivary gland biopsies.

          -  Negative TB test during screening

          -  Immunization up to date as determined by local standard of care.

        Exclusion Criteria:

          -  Previous treatment with AMG 557/MEDI5872.

          -  Evidence of signs or symptoms of a viral, bacterial, or fungal infection within 2
             weeks (14 days) prior to randomization (Day 1) according to the assessment of the
             investigator; any infection requiring IV antibiotic or antiviral treatment within 8
             weeks of randomization (Day 1); history of herpes zoster within 3 months prior to
             randomization (Day 1).

          -  Evidence of significant renal insufficiency

          -  Positive test at screening for hepatitis B, hepatitis C, or human immunodeficiency
             virus (HIV) antibody.

          -  Prior administration of any of the following:

               1. Belimumab in the past 6 months prior to randomization (Day 1);

               2. Rituximab in the past 12 months or CD19+ B cells &lt; 5/µL if rituximab treatment
                  was more than 12 months prior to randomization (Day 1);

               3. Abatacept in the past 6 months prior to randomization (Day 1);

               4. Tumor necrosis factor inhibitors (adalimumab, certolizumab, etanercept,
                  golimumab, infliximab) in the past 3 months prior to randomization (Day 1);

               5. Tocilizumab in the past 3 months prior to randomization (Day 1);

               6. Cyclophosphamide (or any other alkylating agent) in the past 6 months prior to
                  randomization (Day 1); cyclosporine (except for eye drops), tacrolimus,
                  sirolimus, mycophenolate mofetil, azathioprine, or leflunomide in the past 3
                  months prior to randomization (Day 1).

          -  Receiving any of the following:

               1. Corticosteroids: &gt; 10 mg/day oral prednisone (or equivalent); Any change or
                  initiation of new dose within 4 weeks prior to signing the ICF through
                  randomization (Day 1); Intramuscular, IV, or intra-articular corticosteroids
                  within 4 weeks prior to signing the ICF through randomization (Day 1); Any
                  change or initiation of new dose of topical corticosteroids within 2 weeks prior
                  to signing the ICF through randomization (Day 1);

               2. Antimalarials: any increase or initiation of new dose of antimalarials (eg,
                  chloroquine, hydroxychloroquine, quinacrine) within 12 weeks prior to signing
                  the ICF through randomization (Day 1).

               3. Methotrexate: &gt; 20 mg/week methotrexate; Any change or initiation of new dose of
                  methotrexate within 4 weeks prior to signing the ICF through randomization (Day
                  1); Any change in route of administration.

               4. Any increase or initiation of new dose of regularly scheduled nonsteroidal anti
                  inflammatory drugs (NSAIDs) within 2 weeks prior to signing the ICF through
                  randomization (Day 1).

               5. Cevimeline or pilocarpine and cyclosporine eye drops (Restasis): any increase or
                  initiation of new doses within 2 weeks prior to signing the ICF through
                  randomization (Day 1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Dall'Era, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ghaith Noaiseh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Kremlin-bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swindon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 10, 2017</lastchanged_date>
  <firstreceived_date>December 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
